Who are Sinemet Cr's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aldomet, Inbrija, CARBIDOPA AND LEVODOPA, L- DOPA, Carbidopa Levodopa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carbidopa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sinemet Cr — Competitive Intelligence Brief

Sinemet Cr (CARBIDOPA) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatic Amino Acid [EPC]. Area: Metabolic.

marketed Aromatic Amino Acid [EPC] Lysine-specific demethylase 4E Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Sinemet Cr (CARBIDOPA) — Aton. Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sinemet Cr TARGET	CARBIDOPA	Aton	marketed	Aromatic Amino Acid [EPC]	Lysine-specific demethylase 4E	1975-01-01
Aldomet	METHYLDOPA		marketed	methyldopa	Lysine-specific demethylase 4E	1962-01-01
Inbrija	LEVODOPA	Merz	marketed	Aromatic Amino Acid [EPC]	Tyrosine-protein kinase Fyn	1970-01-01
CARBIDOPA AND LEVODOPA	CARBIDOPA,LEVODOPA	BIOCON PHARMA LIMITED	marketed	Aromatic Amino Acid [EPC]
L- DOPA	L- DOPA	Shaare Zedek Medical Center	marketed	Aromatic Amino Acid [EPC]
Carbidopa Levodopa	Carbidopa Levodopa	University of Washington	marketed	Aromatic Amino Acid [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-02-03 — Inbrija · RE43711 · Method of Use · US
2032-11-16 — Inbrija · 8685442 · Formulation · US
2032-11-16 — Inbrija · 8945612 · Formulation · US
2032-11-16 — Inbrija · 8545878 · Formulation · US
2032-11-16 — Inbrija · 9393210 · Formulation · US
2033-10-21 — Inbrija · 12458615 · Method of Use · US

Sponsor landscape (Aromatic Amino Acid [EPC] class)

Aton · 1 drug in this class
BIOCON PHARMA LIMITED · 1 drug in this class
Merz · 1 drug in this class
Shaare Zedek Medical Center · 1 drug in this class
University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sinemet Cr — Competitive Intelligence Brief. https://druglandscape.com/ci/carbidopa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab